{
    "nctId": "NCT04159818",
    "briefTitle": "Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients",
    "officialTitle": "Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients: the TONIC-2 Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic or incurable locally advanced triple negative breast cancer (ER \\< 10%, HER2 IHC 0,1+ or 2+ with no amplification)\n* Metastatic lesion accessible for histological biopsy\n* 18 years or older\n* Maximum of three lines of chemotherapy for metastatic disease and with evidence of progression of disease. Treatment with low-dose doxorubicin in the palliative setting is not allowed.\n* WHO performance status of 0 or 1\n* Measurable or evaluable disease according to RECIST 1.1\n* Disease Free Interval (defined as time between first diagnosis or locoregional recurrence and first metastasis) longer than 1 year\n* Subjects with brain metastases are eligible if these are not symptomatic and free of progression of at least 4 weeks\n* A maximum dosage of 360 mg/m2 of anthracyclines and no previous anthracycline-related cardiac toxicity. In case of radiation in the cardiac area, hypertension, diabetes mellitus or hypercholesterolemia, the left ventricular ejection fraction must be 50% or higher.\n* Adequate bone marrow, kidney and liver function\n\nExclusion Criteria:\n\n* uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris\n* known history of leptomeningeal disease localization\n* history of having received other anticancer therapies within 2 weeks of start of the study drug\n* history of immunodeficiency, autoimmune disease, conditions requiring immunosuppression (\\>10 mgl daily prednisone equivalents) or chronic infections.\n* prior treatment with immune checkpoint inhibitors.\n* active other cancer\n* history of uncontrolled serious medical or psychiatric illness\n* current pregnancy or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}